DALLAS, Feb. 13, 2013 /PRNewswire/ -- The X-Change
Corporation (NASDAQ OTC: XCHC) (X-Change Corp. or the Company), a
U.S. boutique company whose niche is cannabis and hemp based
extracts and products that target medical cannabis, cosmeceutical,
nutraceutical, and social usage solutions through multiple Phytiva
Brand product lines and solutions, is proud to announce it has
entered into a historic agreement with WOLASTOKWIK NeGoot-Gook,
Maliseet Nation at Tobique (the "Maliseet Nation") of New Brunswick, Canada, to participate in the
development and growth of a legal cannabis growing facility,
clinical laboratory, manufacturing and production facility, and
treatment center (the "Agreement").
The Agreement allows for legal cannabis and hemp-based medical
research and treatments with true global significance, as the
operations under the Agreement facilitate medical cannabis and hemp
research, clinical trials, and treatments, among numerous other
opportunities for the parties to the Agreement, for the first time
in North America. And these historical groundbreaking
operations, including medical treatments, will be open to the
citizens of the world in a legal manner. The sovereignty of
the Maliseet Nation allows this venture to accomplish its goals of
helping patients while being legally compliant.
The Agreement was effectuated by the Company's purchase of the
twenty-five percent (25%) stake in a joint venture from Cannabis
Science, Inc. (NASDAQ OTC: CBIS). Details of the Company's
stock-based asset purchase will be released in a Form 8K to be
filed promptly.
X-Change Corp.'s agreement with the Maliseet Nation provides the
parties with unprecedented opportunities to develop a model that
the Company can replicate around the world from cannabis growth, to
clinical research and development, production, and medical
treatment of patients with a wide range of conditions believed to
be effectively treatable with cannabis extract based
formulations. As the parties work to successfully realize the
terms of the Agreement, the Company and the other parties will have
the opportunity to develop additional clinics, laboratories,
production facilities, and hospitals.
It is contemplated by the parties that from working to fulfill
the goals of the Agreement will come the development and discovery
of medicines and modalities to be pursued for approval with the FDA
and other similar governmental bodies.
There are also positive implications with regard to establishing
a global network of resources needed to finally solidify a global
cannabis and hemp seed-to-treatment model that can be accepted as
the industry standard. In pursuit of that goal, the
facilities and services in the Agreement will initially target the
Canadian market as well as that of the
United States with marketing to North American and then
international travelers who have a desire to participate in
cannabis-based medical treatments with full legal
compliance.
Internal estimates calculate that over 30 million people in
the United States and over 100
million globally have the potential to be clients and patients over
the next five years. Since a wide range of ailments has been
targeted, the market potential is in the hundreds of millions of
dollars over the next five to ten years.
"The only thing bigger than this opportunity is my smile,"
stated Robert Kane, President,
X-Change Corp. "It is so very important to establish these
types of facilities for those who are suffering needlessly.
Further, this exciting venture as envisioned by the Agreement
allows for the scientific gathering of data and clinical
information to support efforts to silence critics and persuade
governments with indisputable evidence of the medical value of
these facilities and their treatments."
X-Change Corp.'s Phytiva Brand of products will also be
marketable through the channels described in the Agreement,
promising strong sales growth for these novel and innovative
hemp-based skincare and other products.
About The X-Change Corporation
X-Change Corp. is U.S. Boutique Company whose niche is cannabis and
hemp based extracts and products that target medical cannabis,
cosmeceutical, nutraceutical, and social usage solutions through
multiple Phytiva Brand product lines, products, and services. The
Company issues a stronger outlook for 2013 based on new Phytiva
Brand product lines for the Medical Cannabis Industry as a whole.
These new Phytiva product lines will be launched with Cannabis
based formulations through Medical Cannabis dispensaries, Cannabis
laboratories, and individual legal state or legal foreign grow
operations on a jurisdiction by jurisdiction approved basis.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing works
such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs and products. X-Change Corp. does not undertake any duty nor
does it intend to update the results of these forward-looking
statements.
X-Change Corp.
President & CEO
Robert Kane
info@phytiva.com
www.phytiva.com
1.866.326.5595
SOURCE X-Change Corp.